Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia. Issue 7 (1st May 2019)

• Record Type: Journal Article
• Authors: Medeiros, Bruno C.; Chan, Steven M.; Daver, Naval G.; Jonas, Brian A.; Pollyea, Daniel A.
• Is Part Of: American journal of hematology. Volume 94:Issue 7(2019:Jul.)
• Page Start: 803
• Page End: 811
• Publication Date: 2019-05-01
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.25484
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: Optimization of post‐remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents are being investigated as post‐remission therapy. Identification of recurrent genetic alterations that drive disease progression has enabled the design of new, personalized approaches to therapy for patients with AML. Emerging data suggest that targeted post‐remission therapy, alone or in combination with chemotherapy, may improve outcomes. Results of ongoing clinical trials will further define potential clinical benefits.